

BERBERICH, ANNE, NEE HERTENSTEIN, DR. MED.

GENERAL INFORMATION

Post Doc / Resident University Hospital Heidelberg, Department of Neurology Im Neuenheimer Feld 400 69120 Heidelberg, Germany	A03
---	-----

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2006-2012	Medical training at the Heidelberg University Medical School. Grade: 1.5

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2016	MD thesis in neurology at the University of Heidelberg. Experimental research was done at the German Cancer Research Center (DKFZ) in Heidelberg (supervisor: Prof. Dr. M. Platten) about functional and molecular analysis of effects of the immunomodulatory tryptophan metabolite trnilast on human t cells. Grade: summa cum laude

PROFESSIONAL EXPERIENCE

Year(s)	Education
Since 2015	Postdoctoral researcher at the German Cancer Research Center in Heidelberg, Clinical Cooperation Unit Neurooncology (head: Prof. Dr. W. Wick)
Since 2013	Resident in neurology, Neurology Clinic, University Hospital Heidelberg (chairman: Prof. Dr. W. Hacke - since 10/2014 Prof. Dr. W. Wick). Clinical focus on brain tumors and emergency medicine in neurology

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2014	Wilma-Moser-Prize
2015 - 2016	Stipend of the Rahel-Goitein-Straus program

SELECTED PUBLICATIONS

- [Berberich A](#), Kessler T, Thomé CM, Pusch S, Hielscher T, Sahn F, Oezen I, Schmitt LM, Ciprut S, Hücke N, Ruebmann P, Fischer M, Lemke D, Breckwoldt MO, von Deimling A, Bendszus M, Platten M, Wick W. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. **Clin Cancer Res.** 2019 Jan 1;25(1):253-265.
- [Berberich A](#), Schmitt LM, Pusch S, Hielscher T, Rübmann P, Hücke N, Latzer P, Heßling B, Lemke D, Kessler T, Platten M, Wick W. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. **J Neurooncol.** 2020 Jan;146(1):9-23.
- [Berberich A](#), Hielscher T, Kickingereeder P, Winkler F, Drüscher K, Riedemann L, Arzt M, Kessler T, Platten M, von Deimling A, Wick W, Sahn F, Bendszus M, Wick A. Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. **Int J Radiat Oncol Biol Phys.** 2018 Dec 1;102(5):1472-1480.
- [Hertenstein A](#), Hielscher T, Menn O, Wiestler B, Winkler F, Platten M, Wick W, Wick A. Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. **J Neurooncol.** 2016 Sep;129(3):533-539.
- Wick W, Dettmer S, [Berberich A](#), Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahn F, Platten M. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus

radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro Oncol.* 2019 Jan 1;21(1):95-105.

6. Pfaff E*, Kessler T*, Balasubramanian GP, Berberich A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Dettmer S, Brors B, Platten M, Pfister SM, von Deimling A, Jones DTW#, Wick W#, Sahm F#. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation – the NCT Neuro Master Match (N2M2) pilot study. **Neuro Oncol** 2018;20(6):826-837
7. Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W. Molecular Differences in IDH wild-type Glioblastoma according to MGMT promoter methylation. **Neuro Oncol** 2018;20(3):367-379
8. Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. **Lancet Oncol.** 2016 Dec;17(12):e529-e541.

*shared first authors; #shared senior authors